ADA Slideshow

The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.

Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.

Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.

Panelists say IRA, Most Favored Nation rules and fragmented data are freezing value-based deals for durable one-time therapies.

Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.

At NASP's inSPire2026, covered entities and manufacturers debate 340B program reform, contract pharmacies, and the 2027 rebate model.

Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.